Abstracts Archive - Page 1934 of 2425 - ACR Meeting Abstracts

Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 1784 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis
Takeshi Shoda, Tohru Takeuchi, Takaaki Ishida, Hideyuki Shiba, Youhei Fujiki, Daisuke Wakura, Shuzo Yoshida, Takuya Kotani, Shigeki Makino and Toshiaki Hanafusa, Department of Internal Medicine (I), Osaka medical college, Osaka, Japan
Background/Purpose Many patients with interstitial lung disease (ILD) complicated by microscopic polyangiitis (MPA) show a UIP pattern on chest CT. The prognosis is poorer than…
Abstract Number: 1783 • 2014 ACR/ARHP Annual Meeting
The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose : Histological changes in renal biopsy are the gold standard for establishing the diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In 2010 a…
Abstract Number: 1782 • 2014 ACR/ARHP Annual Meeting
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Pascal Cohen², Boris Bienvenu⁴, Kim Heang Ly⁵, Alain Bruet⁶, Brigitte Gilson⁷, Marc Ruivard⁸, Edouard Pertuiset⁹, Mohamed Hamidou¹⁰, Benjamin Terrier², Christian Pagnoux¹¹, Luc Mouthon², Loic Guillevin¹² and The French Vasculitis Study Group (FVSG)¹², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵CHU Dupuytren, Limoges, Limoges, France, ⁶Department of Nephrology and Internal Medicine, CH de Poissy Saint-Germain-en-Laye, Poissy, France, ⁷Department of Nephrology and Internal Medicine, CH de Verdun, Verdun, France, ⁸CHU Estaing, Clermont–Ferrand, Clermont–Ferrand, France, ⁹Rheumatology, René Dubos Hospital, Pontoise, France, ¹⁰CHU Hôtel Dieu, Nantes, Nantes, France, ¹¹Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose To study the long-term outcomes of 65 patients with non-HBV polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) enrolled in a prospective, randomized, open-label trial,1…
Abstract Number: 1781 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Rennie L. Rhee¹, Susan L Hogan², Caroline J. Poulton², Julie Anne G. McGregor², J. Richard Landis³, Ronald Falk⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²UNC Kidney Center, Chapel Hill, NC, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose Significant advances have been made in the diagnosis and treatment of patients with ANCA-associated vasculitis (AAV). However, little is known about how these advances…
Abstract Number: 1780 • 2014 ACR/ARHP Annual Meeting
Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis
Joanna Ueng¹, Katerina Pavenski² and Laurence Rubin³, ¹Rheumatology/Medicine, University of Toronto, Toronto, ON, Canada, ²Transfusion Medicine, St. Michael's Hospital, Toronto, ON, Canada, ³Rheumatology, St. Michael Hospital, Toronto, ON, Canada
Background/Purpose Microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and Churg-Strauss Syndrome (CSS) are syndromes known as ANCA-associated vasculitis (AAV). In addition to immunosuppressive therapy, plasma…
Abstract Number: 1779 • 2014 ACR/ARHP Annual Meeting
Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality
David Solar-Cafaggi¹, Yemil Atisha-Fregoso¹ and Andrea Hinojosa-Azaola², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: ANCA-associated vasculitides (AAV) are rare, potentially fatal diseases with multiorgan involvement. Evidence for the use of plasmapheresis (PLEX) in patients with severe forms of…
Abstract Number: 1778 • 2014 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life
Grégory Pugnet^1,2, Christian Pagnoux³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen¹, Francois Maurier⁷, Olivier Decaux⁸, Jacques Ninet⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Eric Daugas¹⁸, Thomas Papo¹⁹, Bernard Bonnotte²⁰, Alfred Mahr²¹, Benjamin Terrier¹, Philippe Ravaud²², Luc Mouthon¹ and Loïc Guillevin¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Toulouse University Hospital, Internal Medicine Department, Toulouse, France, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal Medicine, CH, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵CHU Lille, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷CHU Hôtel Dieu, Nantes, Nantes, France, ¹⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ¹⁹Internal Medicine, Bichat Hospital, Paris, Paris, France, ²⁰Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, ²¹Internal Medicine, Hospital Saint-Louis, University Paris 7, Paris, France, ²²Epidemiology, AP-HP Cochin Hospital, Paris, France
Background/Purpose A key goal in the management of ANCA-Associated Vasculitis (AAV) is to improve and preserve health-related quality of life (HRQOL). Several studies have found that…
Abstract Number: 1760 • 2014 ACR/ARHP Annual Meeting
United Kingdom & Ireland Vasculitis Registry – Cross-Sectional Data on the First 1085 Patients
Jan Sznajd^1,2, Alan D. Salama³, David Jayne⁴, Afzal Chaudhry⁵, Michael Robson⁶, Joe Rosa², Neil Basu⁷, Sarah Moran⁸, Michael Venning⁹, Peter Lanyon¹⁰, Asheesh Sharma¹¹, Mark A. Little¹², Richard Watts¹³ and Raashid Luqmani¹⁴, ¹Jagiellonian University Medical College, Krakow, Poland, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁵Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶King’s College London, London, United Kingdom, ⁷Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ⁸Cork University Hospital, Cork, United Kingdom, ⁹Manchester Royal Infirmary, Manchester, United Kingdom, ¹⁰Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹¹University Hospital Aintree Liverpool, Liverpool, United Kingdom, ¹²Trinity College Dublin, Dublin, Ireland, ¹³Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ¹⁴Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom
Background/Purpose Clinical care and research into systemic vasculitis is hampered by its rarity and its presentation to a wide array of medical specialties. We aimed…
Abstract Number: 1759 • 2014 ACR/ARHP Annual Meeting
Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis
Lucas Benarous¹, Benjamin Terrier², Alice Berezne³, Bertrand Dunogué⁴, Hervé Laborde-Casterot⁵, Pascal Cohen⁶, Xavier Puéchal⁶, Nathalie Costedoat-Chalumeau⁷, Claire Le Jeunne⁶, Dominique Choudat⁵, Luc Mouthon⁶ and Loïc Guillevin for the French Vasculitis Study Group⁶, ¹Cochin Hospital, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁴Internal Medicine, Hôpital Cochin, Paris, France, ⁵Médecine du Travail, Cochin Hospital, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Improved therapeutic strategies for ANCA-associated vasculitis (AAV) have transformed acute and life-threatening diseases into chronic ones responsible for marked morbidity that could impact employment,…
Abstract Number: 1758 • 2014 ACR/ARHP Annual Meeting
Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere
Lisa K. Stamp¹, Peter T. Chapman², Richard A. Watts³, Christopher Frampton¹ and John L. O'Donnell⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁴Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand
Background/Purpose: GPA is a rare condition of unknown etiology. Prominent involvement of the upper and lower respiratory tracts suggests that inhaled antigens may trigger systemic…
Abstract Number: 1757 • 2014 ACR/ARHP Annual Meeting
An Analysis of the Incidence and Characteristics of ANCA Positive Vasculitis before and after the Christchurch Earthquake
Ben McGettigan¹, John L. O'Donnell², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Rheumatology, Immunology and Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ²Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ³Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose At 1251 on 22 February 2011 a magnitude 6.4 earthquake struck Christchurch killing up to 185 people and causing widespread damage to buildings in…
Abstract Number: 1756 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases
James T. Rosenbaum¹, Dongseok Choi², Christine Harrington³, Patrick Stauffer⁴, David Wilson⁵, Seema Gupta⁴, Roger Dailey⁴, John Ng⁴, Eric Steele⁴, Patrick Yeatts⁶, Peter Dolman⁷, Valerie White⁷, Gerald Harris⁸, Craig Czyz⁹, Jill Foster⁹, Deepak Edward¹⁰, Hind Alkatan¹⁰, Bobby Korn¹¹, Don Kikkawa¹², Dinesh Selva¹³, Sander Dubovy¹⁴, Chris Alabiad¹⁵, David Tse¹⁵, Michael Kazim¹⁶, Payal Patel¹⁶ and Stephen R. Planck¹⁷, ¹OHSU, Portland, OR, ²Casey Eye Institute, Oregon Health and Science University, Portland, OR, ³Integrated Genomics, Oregon Health & Science University, Portland, OR, ⁴Oregon Health & Science University, Portland, OR, ⁵Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, ⁶Ophthalmology, Wake Forest University, Winston-Salem, NC, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Ohio State Univeristy, Columbus, OH, ¹⁰King Khaled Eye Hospital, Riyadh, Saudi Arabia, ¹¹University of California, San Diego, San Diego, CA, ¹²Ophthalmology, University of California, San Diego, San Diego, CA, ¹³Royal Adelaide Hospital, Adelaide, Australia, ¹⁴University of Miami, Miami, FL, ¹⁵Ophthalmology, University of Miami, Miami, FL, ¹⁶Columbia University, New York City, NY, ¹⁷Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR
Background/Purpose: Gene expression profiling provides diagnostic and therapeutic information in several malignancies, but its role in evaluating inflammatory disease is relatively untested. We hypothesized that…
Abstract Number: 1755 • 2014 ACR/ARHP Annual Meeting
Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation
Melissa Parker, David Gold, Koustubh Ranade and Ethan Grant, Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose ANCA vasculitis is characterized by the presence of autoantibodies directed against MPO, PR3 and other neutrophil proteins. Binding of these autoantibodies to activated neutrophils…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].